Skip to main content

Table 2 Univariate analysis of factors affecting clinical outcome

From: Clinical outcomes of chemoradiotherapy for locally recurrent rectal cancer

  5y OS p† 5y RFS p† 5y LRFS p† 5y DMFS p†
Age (years)         
   < 60 50.5 .653 27.6 .547 57.6 .084   
   ≥60 47.9   36.2   75.9    
Gender         
   Male 55.6 .381 34.8 .340 73.7 .141 42.3 .811
   Female 34.9   27.7   55.7   38.1  
Recurrence-free interval (months)        
   <24 46.4 .675 33.2 .473 59.8 .248 40.6 .663
   ≥24 50.7   26.9   72.9   38.5  
Previous recurrence history        
   0 51.2 .417 36.4 .061 66.9 .834 43.0 .420
   1 38.8   16.7   65.2   33.0  
Symptoms at recurrence         
   Yes 26.3 .025 20.0 .007 40.0 .003 25.8 .047
   No 58.4   38.3   76.2   47.2  
Recurrence site         
   Central 56.0 .494 43.5 .429 67.7 .918 54.2 .305
   Lateral 44.8   26.0   69.1   31.5  
   posterior 36.4   35.3   63.5   36.2  
Pretreatment CEA (ng/mL)         
   ≤5 45.7 .882 41.8 .071 72.1 .154 49.2 .458
   >5 52.8   21.8   59.1   33.8  
Salvage Treatment         
   Surgery + CRT 52.8 .181 35.2 .113 71.0 .379 43.6 .335
   CRT alone 40.6   24.5   55.9   34.6  
Chemotherapy regimen         
   Fluoropyrimidines-alone 47.3 .910 36.7 .572 67.2 .720 42.9 .562
   Irinotecan or Oxaliplatin -based 41.0   22.0   64.7   33.8  
Resection§         
   R0 60.4 .994 35.1 .956 77.7 .529 37.6 .919
   R1 or R2 42.9   34.3   65.6   46.8  
Radiation dose (BED2Gy)         
   <60 46.9 .607 32.3 .281 78.2 .065 41.0 .694
   ≥60 48.3   29.2   52.9   39.2  
  1. *values are percentages of patients; †log rank test. OS, overall survival; § Among 45 patients undergoing surgical resection; RFS, recurrence-free survival; LRFS, locoregional relapse free survival; DMFS, distant metastasis-free survival; CRT, chemoradiotherapy; R0, microscopically radical; R1, microscopically irradical; R2, macroscopically irradical; BED2Gy, biologically equivalent dose in 2-Gy fractions using a linear quadratic model, and the α/β ratio was 10 for acute effects on normal tissues and tumors. CEA, carcinoembryonic antigen.